NasdaqCM - Nasdaq Real Time Price ? USD Beyond Air, Inc. (XAIR) Follow Compare 0.4901 -0.0798 (-14.00%) At close: November 1 at 4:00 PM EDT 0.5043 +0.01 (+2.90%) After hours: November 1 at 5:45 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Beyond Air? Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & GlobeNewswire ? 3 days ago XAIR -14.00% Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting Submitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants on Tuesday, November 5th at 9:00 AM U.S. ET Presentations of Beyond Cancer’s two full posters will take place on November 8th and 9th at the SITC Annual Meeting; ePublications of the posters will be available November 7th Therapeutic efficacy of Low Volume (<1L) UNO demonstrated in both mice and rat tumor models HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical GlobeNewswire ? 26 days ago XAIR -14.00% Beyond Air Partners with Healthcare Links to Expand Access to LungFit? PH System Through Group Purchasing Organizations and Integrated Delivery Networks Revolutionary inhaled nitric oxide technology set to reach broader healthcare systemsGARDEN CITY, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced entering a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting fi GlobeNewswire ? last month XAIR -14.00% Beyond Air to sell 40.39M shares at 51c in private placement Beyond Air has entered into a securities purchase agreement with certain institutional and accredited investors, as well as Company insiders. Under the terms of the securities purchase agreement, the investors have agreed to purchase in a private placement offering 40,392,155 shares of the Company’s common stoc and accompanying warrants to purchase up to 40,392,156 shares of common stock, at a purchase price of $0.51 per common share and accompanying warrant in a private placement priced at-the- TipRanks ? last month XAIR -14.00% Beyond Air terminates loan, security agreements with Avenue Capital Beyond Air has terminated the loan and security agreements with Avenue Capital and entered into an $11.5 million loan agreement with an insider-led investor group. Beyond Air and Avenue Capital have reached an agreement to extinguish the Avenue Capital senior secured term loan for a one-time payment of $17.85 million. This agreement eliminates the debt and interest payments that would have been made to Avenue Capital from October 1, 2024 through June 30, 2026 of $12.0 million. In addition, Avenu TipRanks ? last month XAIR -14.00% Beyond Air Provides LungFit? PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, is proud to announce the deployment of its groundbreaking LungFit? PH system to the U.S. Naval Hospital Guam. This partnership, made possible through collaboration with TrillaMed, marks a significant advancement in the neonatal cr GlobeNewswire ? last month XAIR -14.00% Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital – Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12 million in scheduled debt payments through June 2026 – – $11.5 million loan agreement defers payment of principal and interest through June 2026 - – 60% increase in the number of hospital contracts since July 1, 2024, including U.S. Naval Hospital Guam – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyon GlobeNewswire ? last month XAIR -14.00% Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules – Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 – – Avenue Capital, current insiders, and select group of healthcare-focused investment funds participated in the equity offering – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR GlobeNewswire ? last month XAIR -14.00% Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York on Octob GlobeNewswire ? last month XAIR -14.00% Beyond Air First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag Beyond Air ( NASDAQ:XAIR ) First Quarter 2025 Results Key Financial Results Net loss: US$12.2m (loss narrowed by 13... Simply Wall St. ? 2 months ago XAIR -14.00% Beyond Air? Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 45% compared to the previous quarter ended March 31, 2024 Optimized LungFit PH device continues to expand footprint and strengthen customer base Amir Avniel, Beyond Air Board member and Chief Business Officer, appointed Chief Executive Officer of NeuroNOS, Beyond Air’s wholly owned subsidiary focused on neurological disorders with a lead indication of Autism Spectrum Disorder Reiterates revenue guidance of at least $10 million for FY 2025 GARDEN CITY, N.Y., Aug. 06, 2024 (GLOB GlobeNewswire ? 2 months ago XAIR -14.00% Beyond Air? Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”), today announced the publication of its scientific article, “A safet GlobeNewswire ? 3 months ago XAIR -14.00% Beyond Air? to Report First Fiscal Quarter 2025 Financial Results on August 6 GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it will report financial results for its firs GlobeNewswire ? 3 months ago XAIR -14.00% Beyond Air? To Participate in the BTIG Virtual Biotechnology Conference 2024 GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Offic GlobeNewswire ? 3 months ago XAIR -14.00% Beyond Air? Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth expected to accelerateeach quarter going forward FY 2025 revenue guidance revised to greater than $10 million Implemented capital conservation strategy to reduce cash burn Conference call scheduled for 4:30 p.m. ET today, June 24th GARDEN CITY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a GlobeNewswire ? 4 months ago XAIR -14.00% Beyond Air? Appoints David Webster as Chief Commercial Officer Mr. Webster brings more than 20 years of executive level experience in the life sciences industryGARDEN CITY, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Ca GlobeNewswire ? 4 months ago XAIR -14.00% Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) – Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis – Phase 1a data continue to support feasibility of administering UNO at ultra-high concentrations with immune biomarkers at 50,000 parts per million (ppm) demonstrating an immunogenic response – Phase 1b protocol of UNO in combination with anti-PD-1 antibody therapy filed for regulatory appr GlobeNewswire ? 4 months ago XAIR -14.00% Beyond Air Up 11%, Insiders Still Down After US$3.05m Purchase Insiders who bought US$3.05m worth of Beyond Air, Inc. ( NASDAQ:XAIR ) stock in the last year recovered part of their... Simply Wall St. ? 5 months ago XAIR -14.00% Beyond Air? Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast Conference call scheduled for Monday, June 24th at 4:30 pm ETGARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today GlobeNewswire ? 5 months ago XAIR -14.00% Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting Company to host an event featuring key opinion leaders (KOLs) on Friday, May 31st in Chicago to highlight the ongoing clinical development of UNOHAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinical development program of its Ultra-High Concentration Nitric Oxide (UNO) at the upcoming A GlobeNewswire ? 5 months ago XAIR -14.00% Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return XAIR S&P 500 YTD -74.99% +20.10% 1-Year -78.97% +36.60% 3-Year -95.23% +24.39%
